Legend Biotech
LEGN
88 hedge funds and large institutions have $1.97B invested in Legend Biotech in 2021 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 35 increasing their positions, 17 reducing their positions, and 16 closing their positions.
106% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 17
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
70% more capital invested
Capital invested by funds: $1.16B → $1.97B (+$809M)
19% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 16
14% more call options, than puts
Call options by funds: $3.26M | Put options by funds: $2.87M
3.01% more ownership
Funds ownership: 10.46% → 13.48% (+3%)
2% more funds holding
Funds holding: 86 → 88 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$433M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$50.2M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$29.1M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$25.2M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$24.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$67.6M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$40.1M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$19.5M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$14.9M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$11.5M |
LEGN Hedge Fund Activity: Q3 2021 in Review
88 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Legend Biotech (LEGN) for Q3 2021, worth a combined $1.97B — up 70% from $1.16B a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new LEGN positions and 16 closed out — a net gain of 3 holders — while 35 added to existing stakes and 17 trimmed.
The largest buyer was HHLR Advisors, adding an estimated $433M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $67.6M sold.
- 88 institutional investors held Legend Biotech (LEGN) as of Q3 2021, up from 86 in Q2 2021.
- Funds reported $1.97B of Legend Biotech stock for Q3 2021, up 70% quarter-over-quarter.
- 19 funds opened new Legend Biotech positions in Q3 2021 and 16 closed out, a net change of +3 holders.
- The largest Legend Biotech buyer in Q3 2021 was HHLR Advisors, an estimated $433M added.
- The largest Legend Biotech seller in Q3 2021 was Consonance Capital Management, an estimated $67.6M sold.
Based on aggregated 13F filings for Q3 2021.